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chotic discontinuation and continuation from patients’ and clinicians’ perspectives. 
Further information is needed about the psychometric properties in usual care 
settings. 
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OBJECTIVES: To assess the satisfaction and health-related quality of life (HRQoL) 
improvement of patients enrolled in a pharmacist-run Methadone Maintenance 
Therapy (MMT) program. METHODS: A cohort study design was used to measure 
satisfaction and to evaluate changes in HRQoL of patients after one month of receiv-
ing methadone treatment at Taiping Health Clinic. Respondent’s satisfaction was 
measured by using an eight-item pre-validated questionnaire. A post-survey reliability 
analysis of the questionnaire showed a high internal consistency of the items (Cron-
bach’s α = 0.785). Meanwhile, the HRQoL was measured using a validated EQ-5D 
and EQ-VAS questionnaire that are administered by face-to-face interview in two 
phases, after 1 month interval. The data were analyzed by using both descriptive 
statistics (frequencies and percentages) and inferential statistics (χ2 test, paired t-test 
and the McNemar χ2 test). RESULTS: All 54 patients in MMT clinic participated, but 
only 40 (74.1%) completed this study. Average methadone dose in both phases were 
low (Phase One = 37.4 mg [SD = 22.2], Phase Two = 44.4 mg [SD = 21.3]) that caused 
majority of respondents wishing to increase their current dose. Respondents were not 
satisﬁ ed with needs to come clinic daily (n = 18, 33.4%) and did not believe that 
MMT clinic can help in cessation of drug abuse (n = 9, 16.7%). These two items were 
signiﬁ cantly associated with travelling distance of respondents to clinic (P = 0.001 and 
P = 0.039, respectively). Only pain/discomfort domain of the EQ-5D showed a sig-
niﬁ cant improvement from the baseline (P = 0.035). EQ-VAS score signiﬁ cantly 
improved from 64.69 (SD = 16.7) at baseline to 71.43 (SD = 14.9) during the 1-month 
follow-up (P = 0.008). CONCLUSIONS: MMT program was able to improve patients’ 
QoL even in short duration of time. Improvement on dissatisfactions toward travelling 
distance, needs to travel daily to clinic and inadequate dose will help to increase treat-
ment success. 
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OBJECTIVES: This study aims to compare the HRQoL between patients receiving 
methadone maintenance therapy (MMT) program with those in the rehabilitation 
program. METHODS: This was a cross-sectional study involving 400 randomly 
selected patients from two primary and secondary hospitals and one rehabilitation 
center (PUSPEN) in northern part of Malaysia. Consented patient was interviewed to 
collect their socio-demography, drug consumption and quality of life information. The 
quality of life was measured by using EQ-5D and EQ-VAS questionnaires. Their 
quality of life scores were then compared using independent t-test. RESULTS: Major-
ity of the participants were male with mean age 38.49 (SD = 9.6) in MMT group and 
34.77 (SD = 8.6) in rehabilitation group. Mean duration of treatment for MMT group 
was 17.5 months (SD = 15.74) and rehabilitation group was 7.8 months (SD = 3.52). 
EQ-5D score was signiﬁ cantly (P = 0.01) higher among MMT participants (mean = 
0.783, SD = 0.190) compared to those in rehabilitation program (mean = 0.707, SD 
= 0.227). Participants receiving MMT treatment also had lesser problems in mobility 
(10.5% vs. 21%; P < 0.01), normal activity (6.5% vs. 15%; P < 0.05) and anxiety 
(54.5% vs. 71%; P < 0.001). There was no statistically difference found between the 
groups in self care activity and pain dimensions. However, EQ-VAS score was signiﬁ -
cantly lower in MMT group compared to rehabilitation group (65.5 [SD = 17.9] vs. 
73.5 [SD = 17.6], P < 0.001). CONCLUSIONS: This study shows that treatment for 
patient with substance use disorder with MMT program can provide a better quality 
of life compared to rehabilitation program (PUSPEN). Variation seen between EQ-5D 
and EQ-VAS scores suggest that patients might perceived their health worst than the 
general population value. 
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OBJECTIVES: The aim of the current study was to establish the burden of depression 
(diagnosed, self-reported, and at-risk) in both Europe and Japan. METHODS: Data 
from the 2008 EU and 2008 Japan National Health and Wellness Survey (NHWS) 
were used. Patients were categorized into four groups: diagnosed depression, self-
reported depression, at-risk for depression, and controls. Differences among these 
groups were examined on quality of life (mental (MCS) and physical component 
summary (PCS) scores of the SF-12v2), as well as overall work impairment, controlling 
for demographics and patient characteristics. RESULTS: In the EU, 5848 patients 
(10.9%) were diagnosed, 2037 (3.8%) were self-reported, 13,168 (24.6%) were 
at-risk, and 32,471 (60.7%) were controls. In Japan, 884 (4.4%) were diagnosed, 162 
(0.8%) were self-reported, 5681 (28.4%) were at-risk, and 13,273 (66.4%) were 
controls. After controlling for demographics and patient characteristics, those with 
diagnosed depression (Adjusted Mean [Madj] = 34.4), self-reported depression (M—adj 
= 35.5), and at-risk depression (M—adj = 41.0) reported signiﬁ cantly lower levels of 
MCS scores than controls ((M—adj = 51.10, P’s < 0.0001) across all countries. The 
gap between controls and self-reported depression (b = 3.18, P < 0.0001) and at-risk 
depression (b = 0.63, P < 0.001) was signiﬁ cantly greater in Japan than in the EU. 
Both those with diagnosed (Madj = 46.2) and at-risk (M—adj = 49.4) depression 
reported signiﬁ cantly lower levels of PCS than controls (M—adj = 49.6, P’s < 0.05). 
Finally, those diagnosed with depression (M—adj = 39.2%), self-reported depression 
(M—adj = 30.9%), and at-risk for depression (M—adj = 23.3%) all reported signiﬁ cantly 
more overall work impairment than controls (M—adj = 12.8%). There was also a 
signiﬁ cant interaction, such that the difference in impairment between patients diag-
nosed with depression and controls was signiﬁ cantly greater in Japan (P < 0.05). 
CONCLUSIONS: Levels of diagnosed and self-reported depression were lower in 
Japan than in Europe, yet rates of at-risk depression were higher. Although the burden 
of depression was substantial, the results suggest that the work impairment burden in 
Japan is signiﬁ cantly greater than in the EU. 
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OBJECTIVES: The objective of this project was to assess the burden of depression in 
terms of quality of life and work impairment in the EU and China. METHODS: Data 
were obtained from the 2008 EU and 2009 China National Health and Wellness 
Survey (NHWS). Patients were categorized into four groups: diagnosed depression, 
self-reported depression, at-risk for depression, and controls. Differences among these 
groups were examined on quality of life (mental (MCS) and physical component 
summary (PCS) scores of the SF-12v2), as well as overall work impairment, controlling 
for demographics and patient characteristics. RESULTS: In the EU, 5848 patients 
(10.9%) were diagnosed, 2037 (3.8%) were self-reported, 13168 (24.6%) were 
at-risk, and 32471 (60.7%) were controls. In China, 339 (2.5%) were diagnosed, 348 
(2.6%) were self-reported, 3883 (29.2%) were at-risk, and 8752 (65.7%) were con-
trols. Adjusting for demographics and comorbidities, those with diagnosed (b = 
−16.00, P < 0.0001) and self-reported (b = −14.42, P < 0.0001) depression, and those 
at-risk for depression (b = −9.22, P < 0.0001) reported signiﬁ cantly lower MCS than 
controls. Those diagnosed (b = −3.62, P < 0.0001) and at-risk (b = −0.47, P = 0.0022) 
for depression reported signiﬁ cantly lower PCS than controls. In addition, the MCS 
difference between those with diagnosed, self-reported, or at-risk depression relative 
to controls was signiﬁ cantly greater in Europe than in China (b = 5.88, P < 0.0001; 
b = 5.60, P < 0.0001; b = 3.49, P < 0.0001, respectively). However, the PCS gap 
between patients at-risk for depression and controls was signiﬁ cantly greater in China 
than in Europe (b = −0.99, P < 0.0001). Finally, the work impairment gap between 
patients with diagnosed, self-reported, or at-risk depression and controls was signiﬁ -
cantly greater in Europe than in China (b = −0.35, P = 0.0002; b = −0.40, P < 0.0001; 
b = −0.08, P = 0.0455, respectively). CONCLUSIONS: Depression was associated 
with a substantial burden on patients. The impact of depression on mental quality of 
life and work impairment was greatest in Europe while the impact of depression on 
physical quality of life was greatest in China. 
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OBJECTIVES: To study the extent of brand substitution and switching between Selec-
tive Serotonin Reuptake Inhibitors (SSRI) available on the Pharmaceutical Beneﬁ t 
Scheme (PBS). METHODS: PBS prescription claims data provided by Medicare Aus-
tralia of a 10% random sample of all Australian long-term concession card holders 
covering the time period August 2007 through July 2008 were assessed. Patients had 
to ﬁ ll at least four prescriptions for an SSRI with generics over the 1-year period 
(ﬂ uoxetine [2 doses forms with up to 12 brands], ﬂ uvoxamine [2 strengths with up 
to 5 brands], paroxetine [1 strength with 11 brands] and sertraline [2 strengths with 
up to 13 brands]). The proportions of non-switchers (single brand only) and multiple 
switchers (two or more switches between brands) were determined for each strength 
of each SSRI molecule. RESULTS: A total of 18,691 Concessional patients ﬁ lled at 
least four prescriptions for a SSRI in the 12-month time window. The majority of 
these patients received a single brand over the period: ranging from 49% for ﬂ uvox-
amine to 67% for ﬂ uoxetine. Only a small proportion received three or more brands: 
ranging from 12% for ﬂ uoxetine to 16% for ﬂ uvoxamine. The proportions of multiple 
switchers varied slightly between molecules with: 22% for ﬂ uoxetine, 32% for ﬂ u-
voxamine, 26% for paroxetine and 24% for sertraline. Switching was greater for 
